Objective To explore the effect of Yiqi Liangxue Shengji Formula（ 益气凉血生肌方） on major adverse cardiovascular events（ MACE） in patients with coronary heart disease after percutaneous coronary intervention（ PCI）. Methods A prospective randomized trail method was used to enroll 160 patients with coronary heart disease（ qi deficiency and blood stasis

intermingled blood stasis and heat syndrome） who successfully underwent PCI from October 2015 to December 2017 in Dongfang Hospital Affiliated to Beijing University of Chinese Medicine. They were randomly divided into a control group and a treatment group

with 80 cases in each group. The control group was treated with routine western medicine

and the treatment group was added Yiqi Liangxue Shengji Formula on the basis of routine western medicine treatment for 8 weeks. The incidence of MACE in the 2 groups was recorded and evaluated.Results As of August 2018

the incidence of MACE in the treatment group was 17. 8%

and that in the control group was 38. 3%. The difference between groups was statistically significant（ P < 0. 05）. Logistic regression analysis showed that taking Yiqi Liangxue Shengji Formula after PCI had a negative relationship with the incidence of MACE（ β =-1. 077

P = 0. 008）. Difference in survival rate of the two groups was statistically significant（ P =0. 007）. Conclusion Compared with treating with western medicine alone

the addition of Yiqi Liangxue Shengji Formula may reduce the occurrence of MACE after PCI.